The revolutionary akpulsor offers a simple,
yet elegant answer to the problem posed by patients suffering late stage heart failure. It utilises a novel configuration of the clinically proven, yet currently limited technique of cardiac counterpulsation. Being fully and permanently implantable, it is
designed to provide long-term, cost-effective
treatment and offer a significant improvement in the quality of life
for patients suffering from later stage heart failure: a patient group currently unserved by other medical devices. The akpulsor offers the following key
attributes:
- no contact with blood, leading to a greatly reduced risk of clotting
- no requirement for continuous anti-coagulation therapy
- low trauma implantation procedure, with expected shorter recovery time than for other devices
- fully ambulatory, for maximum quality of life enhancement
- fully implanted with no percutaneous drive connections, to minimise
infection risk
- suitable for a far greater proportion of patients than alternative
devices
Cardiak believes that the combination of low
surgical trauma, and reduced operative risk, will result in simplified post-operative care with correspondingly lower overall treatment costs which will make the akpulsor
a highly attractive proposition for patients and healthcare providers
alike. Tests conducted in the laboratory and pre clinical models have
demonstrated the efficacy of the akpulsor and Cardiak is confident
that the device will be of significant clinical benefit to a wide range
of patients with heart failure.
Click here for further information on the akpulsor.
|
